Correction to: Chronomedicine and type 2 diabetes: shining some light on melatonin

Andrew C. Forrestel¹ · Susanne U. Miedlich¹ · Michael Yurcheshen² · Steven D. Wittlin¹ · Michael T. Sellix¹

Published online: 22 February 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Correction to: Diabetologia
<https://doi.org/10.1007/s00125-016-4175-1>

The authors have been made aware that the following sentence is incorrect: ‘Like IIK7, both ramelteon and tasimelteon have a greater affinity for the MT2 receptor.’ In fact, ramelteon has a greater affinity for MT1 than MT2, whereas tasimelteon, like IIK7, preferentially binds to the MT2 receptor [1]. The authors apologise for this error.

Reference

1. Williams WP III, McLin DE III, Dressman MA, Neubauer DN (2016) Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. *Pharmacotherapy* 36:1028–1041

The online version of the original article can be found at <https://doi.org/10.1007/s00125-016-4175-1>

✉ Michael T. Sellix
Michael_Sellix@urmc.rochester.edu

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 693, Rochester, NY 14642, USA

² UR Medicine Sleep Center, Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA